Overview

Nivolumab+Ipilimumab+RT in MSS mCRC

Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This research is being done to study the effects of the combination of ipilimumab, nivolumab, and radiation therapy in people with metastatic microsatellite stable colorectal cancer. This research study involves the following drugs and interventions: - Ipilimumab - Nivolumab - Radiation Therapy
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
Bristol-Myers Squibb
Treatments:
Ipilimumab
Nivolumab